一名ALK重排的非小细胞肺癌患者对抗PD1治疗和化疗的完全缓解。
Complete response to anti-PD1 therapy and chemotherapy in a patient with ALK-rearranged non-small cell lung cancer.
作者信息
Hu Haoyue, Min Min, Dai Hongchun, Tang Youpan, He Jun
机构信息
Department of Medical Oncology, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, Medicine School of University of Electronic Science and Technology Chengdu, Sichuan, China.
Department of Pathology, The Third Hospital of Mianyang (Sichuan Mental Health Center) Mianyang, Sichuan, China.
出版信息
Int J Clin Exp Pathol. 2025 Jan 15;18(1):37-41. doi: 10.62347/XWHW6190. eCollection 2025.
Abstract
Targeted therapies are effective in non-small cell lung cancer (NSCLC) patients with driver gene mutations. Chemotherapy combined with immunotherapy is also a common treatment strategy in lung cancer. However, in previous studies, patients with ALK (Anaplastic Lymphoma Kinase) rearranged had a low response to immune checkpoint inhibitor (ICI) and the role of immunotherapy in ALK-positive NSCLC patients is unclear. Here, we report a case of a young man with ALK rearranged who demonstrated a complete response to anti-PD1 combination with chemotherapy, which suggests some ALK-rearranged patients with high expression of PD-L1 may permanently benefit from immunotherapy.
摘要
靶向治疗对具有驱动基因突变的非小细胞肺癌（NSCLC）患者有效。化疗联合免疫治疗也是肺癌的一种常见治疗策略。然而，在以往的研究中，ALK（间变性淋巴瘤激酶）重排的患者对免疫检查点抑制剂（ICI）反应较低，免疫治疗在ALK阳性NSCLC患者中的作用尚不清楚。在此，我们报告一例ALK重排的年轻男性患者，其对抗PD1联合化疗表现出完全缓解，这表明一些PD-L1高表达的ALK重排患者可能从免疫治疗中永久获益。
相似文献
1
Complete response to anti-PD1 therapy and chemotherapy in a patient with ALK-rearranged non-small cell lung cancer.一名ALK重排的非小细胞肺癌患者对抗PD1治疗和化疗的完全缓解。
Int J Clin Exp Pathol. 2025 Jan 15;18(1):37-41. doi: 10.62347/XWHW6190. eCollection 2025.
2
Complete and prolonged response to anti-PD1 therapy in an ALK rearranged lung adenocarcinoma.ALK重排的肺腺癌对抗PD-1治疗的完全且持久反应
Lung Cancer. 2020 Aug;146:366-369. doi: 10.1016/j.lungcan.2020.05.008. Epub 2020 May 27.
3
The prognostic role of PD-1, PD-L1, ALK, and ROS1 proteins expression in non-small cell lung carcinoma patients from Egypt.埃及非小细胞肺癌患者中 PD-1、PD-L1、ALK 和 ROS1 蛋白表达的预后作用。
J Egypt Natl Canc Inst. 2022 May 30;34(1):23. doi: 10.1186/s43046-022-00121-8.
4
PD-1 inhibitors plus chemotherapy in EGFR/ALK-positive NSCLC patients with brain metastases and disease progression after EGFR/ALK-TKIs therapy.PD-1 抑制剂联合化疗治疗 EGFR/ALK 阳性 NSCLC 患者脑转移和 EGFR/ALK-TKIs 治疗后疾病进展。
J Cancer Res Clin Oncol. 2022 Dec;148(12):3557-3566. doi: 10.1007/s00432-022-04177-w. Epub 2022 Jul 20.
5
Immunotherapy Alone or in Combination with Chemotherapy as First-Line Treatment of Non-Small Cell Lung Cancer.免疫疗法单独或联合化疗作为非小细胞肺癌的一线治疗。
Curr Treat Options Oncol. 2020 Jul 27;21(8):69. doi: 10.1007/s11864-020-00768-2.
6
Targeted therapy for advanced anaplastic lymphoma kinase (<I>ALK</I>)-rearranged non-small cell lung cancer.晚期间变性淋巴瘤激酶（<I>ALK</I>）重排非小细胞肺癌的靶向治疗。
Cochrane Database Syst Rev. 2022 Jan 7;1(1):CD013453. doi: 10.1002/14651858.CD013453.pub2.
7
Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study.度伐利尤单抗作为晚期非小细胞肺癌的三线或后线治疗药物（ATLANTIC）：一项开放标签、单臂、2 期研究。
Lancet Oncol. 2018 Apr;19(4):521-536. doi: 10.1016/S1470-2045(18)30144-X. Epub 2018 Mar 12.
8
Characteristics of the immune microenvironment and their clinical significance in non-small cell lung cancer patients with ALK-rearranged mutation.具有 ALK 重排突变的非小细胞肺癌患者的免疫微环境特征及其临床意义。
Front Immunol. 2022 Sep 8;13:974581. doi: 10.3389/fimmu.2022.974581. eCollection 2022.
9
Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer.综合基因组分析、肿瘤突变负担和 PD-L1 表达的整合，以鉴定非小细胞肺癌免疫治疗的新型生物标志物。
Cancer Med. 2021 Apr;10(7):2216-2231. doi: 10.1002/cam4.3649. Epub 2021 Mar 2.
10
Crizotinib: a novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged non-small cell lung cancer and beyond.克唑替尼：一种新型的、同类首创的多靶点酪氨酸激酶抑制剂，用于治疗间变性淋巴瘤激酶重排的非小细胞肺癌及其他疾病。
Drug Des Devel Ther. 2011;5:471-85. doi: 10.2147/DDDT.S19045. Epub 2011 Nov 23.
引用本文的文献
1
Case Report: A rare case of ALK-KIF5B gene fusion benefited from treatment with lorlatinib.病例报告：一例罕见的ALK-KIF5B基因融合病例经劳拉替尼治疗后获益。
Front Oncol. 2025 Aug 7;15:1594072. doi: 10.3389/fonc.2025.1594072. eCollection 2025.
本文引用的文献
1
Targeted therapy for advanced anaplastic lymphoma kinase (<I>ALK</I>)-rearranged non-small cell lung cancer.晚期间变性淋巴瘤激酶（<I>ALK</I>）重排非小细胞肺癌的靶向治疗。
Cochrane Database Syst Rev. 2022 Jan 7;1(1):CD013453. doi: 10.1002/14651858.CD013453.pub2.
2
Treatment Sequencing in Patients with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer in Japan: A Real-World Observational Study.日本间变性淋巴瘤激酶阳性非小细胞肺癌患者的治疗序贯：一项真实世界观察性研究。
Adv Ther. 2020 Jul;37(7):3311-3323. doi: 10.1007/s12325-020-01392-0. Epub 2020 May 29.
3
Efficacy of Immune Checkpoint Inhibitor Monotherapy for Advanced Non-Small-Cell Lung Cancer with Rearrangement.免疫检查点抑制剂单药治疗伴有重排的晚期非小细胞肺癌的疗效。
Int J Mol Sci. 2020 Apr 9;21(7):2623. doi: 10.3390/ijms21072623.
4
Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial.阿替利珠单抗联合卡铂加白蛋白紫杉醇化疗与单纯化疗一线治疗转移性非鳞状非小细胞肺癌（IMpower130）：一项多中心、随机、开放标签、III 期临床试验。
Lancet Oncol. 2019 Jul;20(7):924-937. doi: 10.1016/S1470-2045(19)30167-6. Epub 2019 May 20.
5
Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial.阿替利珠单抗联合贝伐珠单抗和化疗治疗非小细胞肺癌（IMpower150）：一项随机、开放标签的 3 期临床试验中具有 EGFR 突变或基线肝转移患者的关键亚组分析。
Lancet Respir Med. 2019 May;7(5):387-401. doi: 10.1016/S2213-2600(19)30084-0. Epub 2019 Mar 25.
6
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC.阿替利珠单抗作为转移性非鳞状 NSCLC 一线治疗药物。
N Engl J Med. 2018 Jun 14;378(24):2288-2301. doi: 10.1056/NEJMoa1716948. Epub 2018 Jun 4.
7
Phase 1/2 Study of the Safety and Tolerability of Nivolumab Plus Crizotinib for the First-Line Treatment of Anaplastic Lymphoma Kinase Translocation - Positive Advanced Non-Small Cell Lung Cancer (CheckMate 370).纳武利尤单抗联合克唑替尼用于治疗间变性淋巴瘤激酶融合阳性的晚期非小细胞肺癌（CheckMate 370）的一线治疗的安全性和耐受性的 1/2 期研究。
J Thorac Oncol. 2018 May;13(5):682-688. doi: 10.1016/j.jtho.2018.02.022. Epub 2018 Mar 6.
8
The function and therapeutic targeting of anaplastic lymphoma kinase (ALK) in non-small cell lung cancer (NSCLC).间变性淋巴瘤激酶（ALK）在非小细胞肺癌（NSCLC）中的作用和治疗靶点。
Mol Cancer. 2018 Feb 19;17(1):52. doi: 10.1186/s12943-018-0810-4.
9
EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis.表皮生长因子受体（EGFR）突变和间变性淋巴瘤激酶（ALK）重排与非小细胞肺癌中PD-1通路阻断的低反应率相关：一项回顾性分析
Clin Cancer Res. 2016 Sep 15;22(18):4585-93. doi: 10.1158/1078-0432.CCR-15-3101. Epub 2016 May 25.
10
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.纳武利尤单抗对比多西他赛治疗晚期非鳞状非小细胞肺癌
N Engl J Med. 2015 Oct 22;373(17):1627-39. doi: 10.1056/NEJMoa1507643. Epub 2015 Sep 27.
Zotero 插件